Diagonal Therapeutics Initiates Natural History Study of Adults Living with Hereditary Hemorrhagic Telangiectasia (HHT), a Rare Bleeding Disorder with No Approved Treatments Diagonal Therapeutics today announced the initiation of a natural history study for HHT in partnership with patient advocacy group Cure HHT.

Diagonal Therapeutics to Present Data at ASH 2024 Demonstrating the Economic and Clinical Burden of Hereditary Hemorrhagic Telangiectasia (HHT) Diagonal Therapeutics to Present Data at ASH 2024 Demonstrating the Economic and Clinical Burden of Hereditary Hemorrhagic Telangiectasia (HHT)

Diagonal Therapeutics to Present at the Cure HHT’s 15th International Scientific Conference Diagonal Therapeutics to Present at the Cure HHT’s 15th International Scientific Conference

Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseases Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies